15,022 Shares in DexCom, Inc. $DXCM Purchased by Centaurus Financial Inc.

Centaurus Financial Inc. acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 15,022 shares of the medical device company’s stock, valued at approximately $943,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Reflection Asset Management acquired a new position in DexCom during the 4th quarter valued at about $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the 1st quarter worth approximately $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter worth approximately $32,000. DV Equities LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $36,000. Finally, Spire Wealth Management boosted its holdings in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Trading Up 12.0%

Shares of NASDAQ DXCM opened at $83.45 on Friday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $87.00. The company has a market cap of $32.20 billion, a price-to-earnings ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45. The business has a fifty day simple moving average of $73.14 and a 200-day simple moving average of $69.20.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.34% and a net margin of 20.12%.DexCom’s revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the business posted $0.48 EPS. Sell-side analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Insider Buying and Selling

In other news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,506 shares of company stock valued at $7,205,258. Company insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price target (up from $88.00) on shares of DexCom in a research note on Friday. Bank of America lowered their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Sanford C. Bernstein set a $77.00 price objective on DexCom in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $88.12.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.